Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 10/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5671097 | 0.98 | ADA (0.50) | ADACYP3A4NPSR1SMN1; SMN2LMNA | |
| SCHEMBL6133548 | 0.90 | ADA (0.61) | ADAMAPK1POLB | |
| SCHEMBL5672312 | 0.89 | KDM4E (0.43) | ADALMNAMAPTMEN1KMT2A | |
| SCHEMBL5671885 | 0.87 | ADA (0.53) | ADASMN1; SMN2LMNAMAPTMEN1 | |
| SCHEMBL5673460 | 0.86 | ADA (0.50) | ADACYP3A4POLB | |
| SCHEMBL5671213 | 0.85 | ADA (0.49) | ADACYP3A4MAPTPOLB | |
| SCHEMBL5671871 | 0.84 | ADA (0.48) | ADAKDM4EPOLB | |
| SCHEMBL5674019 | 0.83 | ADA (0.44) | ADASMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL5672355 | 0.83 | ADA (0.46) | ADASMN1; SMN2MAPTHTTMEN1 | |
| SCHEMBL5671001 | 0.83 | ADA (0.49) | ADASMN1; SMN2LMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064144-B2 | Imidazole derivatives as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2006-06-20 | — | — | US | claimed |
| US-20040236114-A1 | Imidazole derivatives as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2004-11-25 | — | — | US | claimed |
| US-7064144-B2 | Imidazole derivatives as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2006-06-20 | — | — | US | disclosed |
| US-20040236114-A1 | Imidazole derivatives as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236114-A1 | Imidazole derivatives as adenosine deaminase inhibitors | ADA, ADAR, IMPDH1 | ADA 1/4885CYP3A4 311/4885NPSR1 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.